LONDON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the European Medicines Agency has authorized an update to the Summary of Product Characteristics (SmPC) for Baxter's ...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis ...
Baxter International Inc., a global, diversified healthcare company, has received approval from China State Food and Drug Administration (SFDA) for Advate [Recombinant Human Coagulation Factor VIII ...
The hemophilia A treatment Advate is the cornerstone to the future of Baxalta ($BXLT), the company that was created when Baxter International ($BAX) spun off its drug ...
EAGAN, Minn., Dec. 16, 2020 /PRNewswire/ -- In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results